BR112017022857A2 - composto, método para preparar o composto, composição - Google Patents

composto, método para preparar o composto, composição

Info

Publication number
BR112017022857A2
BR112017022857A2 BR112017022857-2A BR112017022857A BR112017022857A2 BR 112017022857 A2 BR112017022857 A2 BR 112017022857A2 BR 112017022857 A BR112017022857 A BR 112017022857A BR 112017022857 A2 BR112017022857 A2 BR 112017022857A2
Authority
BR
Brazil
Prior art keywords
compound
preparing
composition
ameliorate
salts
Prior art date
Application number
BR112017022857-2A
Other languages
English (en)
Other versions
BR112017022857B1 (pt
Inventor
Choi Gildon
Dal Rhee Sang
Ali Imran
Hak Chae Chong
Hee Park Seok
Kook Jeon Moon
Sook Lee Youn
Lee Kwangho
Original Assignee
Research & Business Foundation Sungkyunkwan University
Korea Research Institute Of Chemical Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research & Business Foundation Sungkyunkwan University, Korea Research Institute Of Chemical Technology filed Critical Research & Business Foundation Sungkyunkwan University
Publication of BR112017022857A2 publication Critical patent/BR112017022857A2/pt
Publication of BR112017022857B1 publication Critical patent/BR112017022857B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

trata-se de derivados de pirrolidina carboxamido, isômeros ópticos dos mesmos e sais dos mesmos que têm a capacidade de prevenir, melhorar e/ou tratar afecções inflamatórias, incluindo doença inflamatória intestinal, e métodos para preparar e usar os mesmos.
BR112017022857-2A 2015-07-08 2016-07-08 Composto, método para preparar o composto, uso de uma composição BR112017022857B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150097040 2015-07-08
KR20150097040 2015-07-08
PCT/US2016/041563 WO2017008033A1 (en) 2015-07-08 2016-07-08 Pyrrolidine carboxamido derivatives and methods for preparing and using the same

Publications (2)

Publication Number Publication Date
BR112017022857A2 true BR112017022857A2 (pt) 2018-07-17
BR112017022857B1 BR112017022857B1 (pt) 2023-09-26

Family

ID=57686085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022857-2A BR112017022857B1 (pt) 2015-07-08 2016-07-08 Composto, método para preparar o composto, uso de uma composição

Country Status (25)

Country Link
US (3) US20170008924A1 (pt)
EP (1) EP3265443B1 (pt)
JP (1) JP6692371B2 (pt)
KR (1) KR101963559B1 (pt)
CN (2) CN107531753A (pt)
AU (1) AU2016290963B2 (pt)
BR (1) BR112017022857B1 (pt)
CA (1) CA2980001C (pt)
CL (1) CL2017002689A1 (pt)
CO (1) CO2017010530A2 (pt)
DK (1) DK3265443T3 (pt)
EA (1) EA033342B1 (pt)
ES (1) ES2784703T3 (pt)
HK (1) HK1243078A1 (pt)
IL (1) IL254327B (pt)
MX (1) MX2017013335A (pt)
MY (1) MY189670A (pt)
NZ (1) NZ735250A (pt)
PH (1) PH12017501790A1 (pt)
PL (1) PL3265443T3 (pt)
PT (1) PT3265443T (pt)
SA (1) SA517390034B1 (pt)
SG (1) SG11201707145QA (pt)
UA (1) UA121890C2 (pt)
WO (1) WO2017008033A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784703T3 (es) 2015-07-08 2020-09-30 Research & Business Found Sungkyunkwan Univ Derivados de la pirrolidina carboxamida y métodos para preparar y utilizar la misma
WO2019168357A1 (en) * 2018-02-28 2019-09-06 Bridge Biotherapeutics, Inc. Water soluble salts of lipidated peptides and methods for preparing and using the same
WO2020097344A1 (en) * 2018-11-08 2020-05-14 Arizona Board of Regents on Behalf Arizona State University Synthetic immunomodulation with a crispr super-repressor in vivo
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
WO2021075870A1 (ko) * 2019-10-17 2021-04-22 주식회사 스템모어 Rip 키나아제 억제제를 포함하는 탈모 방지 또는 발모 촉진용 조성물
KR102268702B1 (ko) * 2019-10-17 2021-06-24 주식회사 에피바이오텍 Rip 키나아제 억제제를 포함하는 탈모 방지 또는 발모 촉진용 조성물
KR102394875B1 (ko) * 2021-05-11 2022-05-06 주식회사 비드테크 피롤리딘을 링커로 포함하는 화합물 및 이를 포함하는 약학 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3839127A1 (de) * 1988-11-19 1990-05-23 Hoechst Ag Pyrrolidon-2-carbonsaeure-derivate mit psychotroper wirkung
AUPM906594A0 (en) 1994-10-26 1994-11-17 Peptide Technology Limited Synthetic polyunsaturated fatty acid analogues
AU726594B2 (en) * 1996-05-01 2000-11-16 Ortho-Mcneil Pharmaceutical, Inc. Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders
EP1004578B1 (en) * 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
JP2002297664A (ja) 2001-04-03 2002-10-11 Fuji Photo Film Co Ltd 画像データ提供装置および画像データ提供プログラム
US20030022938A1 (en) 2001-06-25 2003-01-30 Burstein Sumner H. N-fatty acid-amino acid conjugates and therapeutic uses
DE10259672A1 (de) * 2002-12-18 2004-07-01 Basf Ag Verfahren zur Herstellung von Alkoxycarbonylamino-triazinen
JP2006157623A (ja) * 2004-11-30 2006-06-15 Funai Electric Co Ltd 放送受信装置
WO2006113942A2 (en) * 2005-04-20 2006-10-26 Schering Corporation Method of inhibiting cathepsin activity
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
US8797234B2 (en) 2008-06-26 2014-08-05 Sharp Kabushiki Kaisha Display device including light-transmitting cover with lens portion and electronic device including same
AU2009283821B2 (en) 2008-08-18 2014-05-29 Entera Bio Ltd. Methods and compositions for oral administration of proteins
KR101033041B1 (ko) 2008-11-13 2011-05-09 조선대학교산학협력단 경보장치 고정 장치
WO2010059922A1 (en) * 2008-11-21 2010-05-27 Ligand Pharmaceuticals Incorporated Pyrrolidine carboxamide compounds
KR101151878B1 (ko) 2010-06-08 2012-05-31 미원상사주식회사 지방산 트리펩타이드염 및 이를 함유하는 항균 조성물
KR20100110282A (ko) 2010-08-16 2010-10-12 황규태 쓰레기봉투용 뚜껑
KR101348284B1 (ko) * 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
KR20120048864A (ko) 2010-11-08 2012-05-16 주식회사 네오디엠 트리 펩타이드 유도체를 함유한 아토피 피부염 예방 및 치료용 조성물과 그 제조방법
KR20130038426A (ko) 2011-10-07 2013-04-18 성균관대학교산학협력단 지방산이 결합된 항당뇨 펩티드가 소수성 결합된 글리콜 키토산 히드로겔 및 이를 포함하는 당뇨병 예방 또는 치료용 약학적 조성물
KR101359886B1 (ko) 2011-12-28 2014-02-12 성균관대학교산학협력단 스매드 6번(Ｓｍａｄ６)으로부터 유래된 펩타이드를 유효성분으로 포함하는 패혈증 또는 패혈성 쇼크의 치료용 조성물
WO2013190497A2 (en) * 2012-06-21 2013-12-27 Radikal Therapeutics Inc. Compositions and methods for treatment of inflammatory diseases of the lung
WO2015057820A2 (en) * 2013-10-15 2015-04-23 Roberts S Kenny Peptide constructs and well-defined aggregates thereof
ES2784703T3 (es) 2015-07-08 2020-09-30 Research & Business Found Sungkyunkwan Univ Derivados de la pirrolidina carboxamida y métodos para preparar y utilizar la misma

Also Published As

Publication number Publication date
US20180208625A1 (en) 2018-07-26
DK3265443T3 (da) 2020-03-09
WO2017008033A8 (en) 2017-11-16
EP3265443A4 (en) 2018-11-07
PH12017501790A1 (en) 2018-04-02
KR101963559B1 (ko) 2019-03-28
CN115368438A (zh) 2022-11-22
UA121890C2 (uk) 2020-08-10
CL2017002689A1 (es) 2018-04-20
CO2017010530A2 (es) 2018-01-05
PL3265443T3 (pl) 2020-06-29
KR20170127000A (ko) 2017-11-20
HK1243078A1 (zh) 2018-07-06
MX2017013335A (es) 2018-06-06
EP3265443B1 (en) 2020-01-08
NZ735250A (en) 2020-08-28
EA033342B1 (ru) 2019-09-30
US20230018246A1 (en) 2023-01-19
SA517390034B1 (ar) 2021-12-23
US20170008924A1 (en) 2017-01-12
BR112017022857B1 (pt) 2023-09-26
US11365215B2 (en) 2022-06-21
WO2017008033A1 (en) 2017-01-12
AU2016290963A1 (en) 2017-09-28
EA201791945A1 (ru) 2018-06-29
CN107531753A (zh) 2018-01-02
EP3265443A1 (en) 2018-01-10
ES2784703T3 (es) 2020-09-30
JP2018519244A (ja) 2018-07-19
IL254327A0 (en) 2017-11-30
MY189670A (en) 2022-02-24
PT3265443T (pt) 2020-02-14
IL254327B (en) 2021-04-29
CA2980001A1 (en) 2017-01-12
SG11201707145QA (en) 2017-10-30
AU2016290963B2 (en) 2019-06-27
JP6692371B2 (ja) 2020-05-13
CA2980001C (en) 2021-05-04

Similar Documents

Publication Publication Date Title
BR112017022857A2 (pt) composto, método para preparar o composto, composição
BR112018008746A2 (pt) composições e métodos para a inibição de atividade de arginase
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
EA201790398A1 (ru) Способы лечения заболевания печени
MA47574A (fr) Inhibiteurs de la sulfoximine glycosidase
ES2721001T3 (es) Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
DK3167078T3 (da) HCBI-, MSBI-, MSSI- og CMI-sekvenser til en tidlig markør for fremtidig udvikling af cancer og sygdomme i CNS og som et target for behandling og forebyggelse af disse sygdomme
DK3277295T3 (da) Sammensætning til behandling af en patogen, metabolisk tarmmikrobiotatilstand og afledte sygdomme
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
EP3307068A4 (en) Mct4 inhibitors for treating disease
DK3242957T3 (da) Bakterieholdige sammensætninger og fremgangsmåder til anvendelse af samme til behandling og/eller forebyggelse af gastrointestinale, metaboliske og/eller andre sygdomme
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EP3316887A4 (en) GLS1-INHIBITOR TO TREAT DISEASES
IT201700051909A1 (it) Calandra perfezionata
BR112017022924A2 (pt) métodos para aperfeiçoamento hidráulico de culturas.
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
EA201691493A1 (ru) Замещенные n-арилпиридиноны
BR112016015712A2 (pt) método de tratamento de doenças hepáticas.
CL2019001649A1 (es) Método para el control de enfermedades bacterianas de plantas utilizando derivados de carboxamida.
DK3307323T3 (da) Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf
EP3781695A4 (en) IMPORT OF MITOCHONDRIAL RNA FOR TREATMENT OF MITOCHONDRIAL DISEASE
DK3319970T3 (da) Pyrido-oxazinonderivater som tnap-hæmmere

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2016, OBSERVADAS AS CONDICOES LEGAIS